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froOBJECTIVES The study sought to assess feasibility, safety, and potential efﬁcacy of a novel implantable extra-aortic
counterpulsation system (C-Pulse) in functional class III and ambulatory functional class IV heart failure (HF) patients.
BACKGROUND 30% to 40% of HF patients suffer from poor functional status and quality of life (QoL) but are not
in need of end-stage treatments. We undertook a multicenter single-arm study to assess the C-Pulse System in such
patients.
METHODS New York Heart Association (NYHA) functional class III or ambulatory functional class IV HF patients were
eligible. Safety was assessed continuously through 12 months. Efﬁcacy measurements included changes from baseline
to 6 and 12 months in NYHA functional class, Minnesota Living with Heart Failure (MLWHF) and Kansas City Cardiomy-
opathy Questionnaire (KCCQ) scores, 6-min walk distance (6MWD), and exercise peak oxygen consumption (pVO2;
6 months only).
RESULTS Twelve men and 8 women (56.7  7 years, 34 to 71 years of age) with ischemic (n ¼ 7) or nonischemic (n ¼ 13)
cardiomyopathy were implanted. There was no 30-day mortality and no neurological events or myocardial infarctions
through 12 months. At 6 months, there were 3 deaths (1 device-related). One-year survival was 85%. At 6 months, C-
Pulse produced improvements in NYHA functional class (3.1  0.3 to 1.9  0.7, p ¼ 0.0005), MLWHF (63.6  19.9 to
40.2  23.2, p ¼ 0.0005), and KCCQ scores (43.6  21.1 to 65.6  21.5, p ¼ 0.0002), but not 6MWD (275.5  64.0 to
296.4  104.9, p ¼ NS) or pVO2 (14.5  3.6 to 13.1  4.4, p ¼ NS). Improvements continued at 12 months, with 6MWD
change becoming statistically signiﬁcant (336.5  91.8, p ¼ 0.0425).
CONCLUSIONS Use of C-Pulse in this population is feasible, appears safe, and improves functional status and QoL.
A prospective, multicenter, randomized controlled trial is underway. (C-Pulse IDE Feasability Study-A Heart Assist
System; NCT00815880) (J Am Coll Cardiol HF 2014;2:526–33) © 2014 by the American College of Cardiology
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527AB BR EV I A T I O N S
AND ACRONYM S
6MWD = 6-min walk distance
CT = computed tomography
LVAD = left ventricular
assist device
NYHA = New York Heart
Association
pVO2 = peak oxygen
consumption
PIL = percutaneous interface
lead
QoL = quality of lifeF unctional status and quality of life (QoL)remain poor for at least 30% to 40% of chronicheart failure patients, who remain categorized
in New York Heart Association (NYHA) functional class
III or IV despite optimal evidence-based drug and elec-
trophysiological device therapies (1). These patients
with advanced heart failure are also at the greatest
risk for heart failure–related hospitalization and mor-
tality, with a 1-year mortality rate of at least 10% to
15% (2–4). While therapies such as cardiac transplanta-
tion or left ventricular assist devices (LVADs) may
beneﬁt the subset of this population with end-stage
disease deﬁned by the American College of Cardiol-SEE PAGE 534ogy/American Heart Association as Stage D heart fail-
ure, these measures are generally not indicated for
the vast majority of patients with Stage C heart failure
(5). Moreover, the small number of available donor or-
gans limits the application of cardiac transplantation,
and LVADs are limited by the blood-contacting nature
of their design and need for chronic anticoagulation,
resulting in signiﬁcant device-related adverse events
of stroke, major bleeding, infection, and device failure
(6). Thus, there is an unmet need for additional thera-
pies for American College of Cardiology/American
Heart Association Stage C and NYHA functional class
III and ambulatory functional class IV heart failure
patients.
One emerging approach to these patients is
through the use of chronic ambulatory aortic coun-
terpulsation (7–9). Aortic counterpulsation is a well-
established mode of circulatory support that works
by reducing left ventricular after-load during systole
and augmenting blood pressure and systemic and
coronary perfusion during diastole (10–12). While the
application of aortic counterpulsation in acutely ill
patients involves the use of an intra-aortic system
(the intra-aortic balloon pump), implantable intra-
and extra-aortic counterpulsation systems have been
developed for chronic ambulatory use (13–16). One
such system, the C-Pulse System (Sunshine Heart,
Inc., Eden Prairie, Minnesota), includes a novel
implantable, nonobligatory, non–blood contacting
counterpulsation heart assist pump developed for
minimally invasive implantation without the need
for cardiopulmonary bypass (15,16).Thoratec; and has served on the Data Safety and Monitoring Board for BioSt
stock options in Sunshine Heart, Inc.; and has received consulting fees. Dr. V
stock options. All other authors have reported that they have no relationshi
Manuscript received January 28, 2014; revised manuscript received April 14The C-Pulse System was designed to pro-
vide an effective low-risk and low-cost me-
chanical heart assist device for use in patients
with chronic American College of Cardiology/
American Heart Association Stage C and NYHA
functional class III and ambulatory functional
class IV heart failure. The device is designed to
be turned off safely or weaned if there is sus-
tained cardiac recovery and similarly, in fail-
ure modes, is considered to have a low risk of
death or disability, other than the recurrence
of heart failure symptoms. No anticoagulants
are required, reducing the risk of bleeding
complications, and the extravascular nature of
the implant mitigates the risk of intravascular
thrombus formation, thromboembolism, and blood-
borne infection. Preliminary studies suggest that this
method of counterpulsation is feasible and safe (15,16).
The present study was designed to further assess the
feasibility, safety, and potential efﬁcacy of the C-Pulse
System in the intended population.METHODS
PATIENTS. Patients 18 to 75 years of age were eligible
for this study if they had American College of Cardio-
logy/American Heart Association Stage C heart failure
with a left ventricular ejection fraction #35%
and remained in NYHA functional class III or ambula-
tory functional class IV despite optimal medical ther-
apy. Patients were required to have been receiving
optimal drug treatment (e.g., angiotensin-converting
enzyme inhibitors, beta-blockers) for at least 3
months and to have had a biventricular pacemaker
for at least 3 months, if indicated. Patients were
also required to have an implantable cardioverter-
deﬁbrillator, if indicated. Other major inclusion
criteria included a 6-min walk distance (6MWD) be-
tween 100 to 350 m and exercise peak oxygen con-
sumption (pVO2) between 10 and 18 ml/kg/min for
men and 9 and 16 ml/kg/min for women. Major exclu-
sion criteria included severe renal failure (estimated
glomerular ﬁltration rate <40 ml/min/1.73 m2), severe
chronic respiratory disease (forced expiratory volume
#0.9 l/min), severe right heart failure (central venous
pressure $20 mm Hg, elevated liver function tests
beyond 3 times the upper limit of normal, or theable. Dr. Peters holds intellectual property, stock, or
erta is an employee of Sunshine Heart, Inc. and holds
ps relevant to the contents of this paper to disclose.
, 2014, accepted April 15, 2014.
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528presence of ascites), signiﬁcant ascending aortic dis-
ease and/or calciﬁcation, moderate or severe aortic
valve incompetence, previous aortic surgery, or the
presence of aortocoronary artery grafts. Eligible pa-
tients underwent computed tomography (CT) scan-
ning of the chest to ensure the ascending aortawas free
of signiﬁcant disease and/or calciﬁcation and within
anatomic constraints. A complete list of inclusion and
exclusion criteria may be found at www.clinicaltrials.
gov (NCT00815880).
The study was conducted in accordance with Code
of Federal Regulations Parts 11, 50, 54, 56, and 812,
Declaration of Helsinki and International Conference
for Harmonization Guidelines for Good Clinical Prac-
tices. The institutional review board of each partici-
pating center approved the study protocol, and all
patients provided written informed consent. The
study was performed under an Investigational Device
Exemption from the U.S. Food and Drug
Administration.
STUDY DESIGN. The C-Pulse study was a prospective,
open-label, single-arm feasibility trial undertaken
at 7 centers in North America (Online Appendix).
Following baseline testing, eligible patients under-
went implantation of the C-Pulse System (Figure 1).
The C-Pulse System consists of a surgically implanted
extra-aortic balloon cuff and epicardial electrocardi-
ography sense lead; an exchangeable, wire-wound
percutaneous interface lead (PIL); and an externalFIGURE 1 Overview of the C-Pulse System
(A) Components of the C-Pulse System (see text for details). (B) Cuff in
minimizing strain in the balloon and the aortic wall and maximizing volubattery-powered pneumatic driver (Figure 1A). Under
general anesthesia, the cuff was wrapped around the
ascending aorta and the bipolar epicardial lead was
placed on the left ventricle. The surgery did not
require use of cardiopulmonary bypass or systemic
anticoagulation. The implantation was done through
a standard median sternotomy incision or minimally
invasively through either a limited right parasternal
thoracotomy procedure or via a hemisternotomy
approach. The gas-line and lead were connected to
the “Y” connector of the PIL, which was tunneled
under the rectus sheath to an exit site located on the
abdomen. A driver was attached to the patient
connector and a programmer was used to adjust cuff
inﬂation volume and timing of inﬂation and deﬂation
in relation to the cardiac cycle to optimize the coun-
terpulsation effect (Figure 1B). Balloon inﬂation was
timed via the programmer to begin right after the
dicrotic notch, while deﬂation started during the pre-
ejection phase and continued during the ejection
phase of systole in such a way that 70  10% of the
balloon was deﬂated at the start of ejection. Patients
were discharged from the hospital once heart failure
medications were re-established and the patients
were ambulatory and able to demonstrate the ability
to care for the exit site and manage the driver.
Patients were scheduled to be seen by the heart
failure clinician-investigator and study coordinator at
1, 3, 6, and 12months post-implant. During the primaryﬂation causes a “thumbprint” deﬂection of the aortic wall, thus
me displacement per beat (10 to 24 cc/beat).
TABLE 1 Characteristics of the Study Patients (N ¼ 20)
Age (range), yrs 56.7  9.1 (34.0–71.0)
Sex
Female 40.0% (8/20)
Race
Black/African American 15.0% (3/20)
Caucasian 80.0% (16/20)
Comorbidities
Arrhythmia 55.6% (10/18)
Hyperlipidemia 65.0% (13/20)
Diabetes mellitus 25.0% (5/20)
Smoking history 75% (15/20)
Cardiomyopathy 100% (20/20)
Ischemic 35.0% (7/20)
Nonischemic 65.0% (13/20)
Blood chemistry
Creatinine, mg/dl 1.3  0.5 (20) [0.7, 2.4]
Bilirubin, mg/dl 1.0  0.5 (20) [0.5, 2.1]
AST, U/l 22.9  10.5 (20) [8.0, 52.0]
ALT, U/l 25.7  19.0 (20) [2.4, 95.0]
Intermacs patient proﬁle
3: Stable but inotrope dependent 15.0% (3/20)
5: Exertion intolerant 40.0% (8/20)
6: Exertion limited 35.0% (7/20)
7: Advanced NYHA functional class III 10.0% (2/20)
NYHA functional class
III 90.0% (18/20)
IV 10.0% (2/20)
Drugs
Beta-blocker 100.0% (20/20)
Angiotensin-converting enzyme inhibitor 50.0% (10/20)
Angiotensin II receptor blocker 25.0% (5/20)
Aldosterone antagonist 55.0% (11/20)
Loop diuretic 85.0% (17/20)
Thiazide 20.0% (4/20)
Nitrate 20.0% (4/20)
Non-nitrate vasodilator 20.0% (4/20)
Inotrope 20.0% (4/20)
Digoxin 75.0% (15/20)
Cardiac resynchronization therapy 45.0% (9/20)
Implantable cardioverter-deﬁbrillator therapy 100.0% (20/20)
Values are mean  SD (range), % (n/N), or mean  SD (n) (minimum, maximum).
ALT ¼ aspartate aminotransferase; AST ¼ alanine aminotransferase; NYHA ¼ New York Heart
Association.
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529period of follow-up (the ﬁrst 6 months), the C-Pulse
System was intended to be used at least 20 h per day.
The non–blood contacting feature of the C-Pulse Sys-
tem allows the device to be intermittently turned off as
tolerated. This enables the patient to be “untethered”
from the device, allowing freedom for personal hy-
giene and convenience. Follow-up visits included a
repeat of baseline tests: physical examination, medi-
cation summary, and assessment of NYHA functional
class, QoL as measured by the Minnesota Living with
Heart Failure questionnaire and the Kansas City Car-
diomyopathy Questionnaire, 6MWD, and pVO2
(repeated at 6 months only). Safety data, including
adverse events, was collected continuously. The CT
was repeated at 6 months only. Data were collected via
electronic data capture screens referred to as e-case
report forms and independently monitored. Core lab-
oratories were used to provide data on CT scans
(Cardiovascular Core Labs, Washington, DC), echo-
cardiograms (Cardiovascular Core Labs, Washington,
DC), and pVO2 testing (Henry Ford Health System,
Detroit, Michigan). Functional status assessments and
QoL testing (NYHA functional classiﬁcation and QoL
scoring, respectively) were conducted using stan-
dardized and validated approaches and questionnaires
(1,17). Adverse events were recorded by the clinical
sites and adjudicated by an independent Clinical
Events Committee (see the Online Appendix). Adverse
event deﬁnitions were based on Version 2.2 adverse
event deﬁnitions for the Intermacs registry (2,18).
STATISTICAL ANALYSIS. This feasibility study was
designed to assess the safety and potential beneﬁt of
the C-Pulse System in patients with NYHA functional
class III-ambulatory functional class IV heart failure.
As with most Investigational Device Exemption feasi-
bility studies, the primary focus of the U.S. Food and
Drug Administration and device manufacturer is on
device safety andwhether its potential beneﬁt justiﬁes
the risks of use. At this stage, endpoints and sample
size are not statistically driven; however, study results
may be useful in designing the pivotal study, in
particular for endpoint selection and assumptions
used in power calculation. A sample size of 20
implanted patients was considered clinically sufﬁcient
by the U.S. Food and Drug Administration to provide
preliminary data on both safety and potential efﬁcacy.
Absolute changes in efﬁcacymeasures frombaseline to
follow-up were included in the statistical plan. An in-
dependent Data and Safety Monitoring Board (see the
Online Appendix) monitored safety. SAS statistical
software (release 9.3 TS1M3, SAS Institute, Cary, North
Carolina) was used.
The safety of the C-Pulse System was evaluated by
reviewing a composite of the device-related adverseevents through 6 months, as adjudicated by the
Clinical Events Committee. The composite device-
related adverse event rate included death, major
infection, aortic disruption, neurological dysfunction,
myocardial infarction, or any other device-related
adverse event. Safety was deﬁned as the composite
device-related adverse event rate and reported with
its 95% 2-sided exact conﬁdence interval. The com-
posite device-related adverse event rate is assumed to
follow the binomial distribution and deﬁned as the
percent of patients who experience at least 1 of the
TABLE 2 Characteristics of the Implant Procedure (N ¼ 20)
Incision to dressing time, min 165.7  42.4 (19)
156.0 [98.0, 247.0]
Anatomical approach
Full sternotomy 70.0% (14/20)
Partial sternotomy 10.0% (2/20)
Right vertical parasternal 20.0% (4/20)
Time in ICU, days 2.2  2.6 (19)
1.1 [0.6, 11.1]
Time in hospital, days 9.9  4.2 (19)
8.0 [4.0, 19.0]
Values are mean  SD (n), median (minimum, maximum) or % (n/N).
ICU ¼ intensive care unit.
TABLE 3
(N ¼ 20)
Composite
Device-rel
Within 3
30 days
Neurologi
Aortic disr
Myocardia
Major infe
Localize
(per
Exit site
Internal
Sepsis
Any other
Acute ren
Values are
been adjud
disruption a
mography w
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AE ¼ adv
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530primary adverse events. All patients are included in
reporting of safety.
Baseline and follow-up data were used to assess
differences in NYHA functional class, QoL, and exer-
cise variables before and after implant. The statistical
analysis used data from paired samples. Only those
patients providing paired assessments were included
in the efﬁcacy analyses. The mean point estimates and
their respective standard deviations are presented for
NYHA functional class, QoL scores, 6MWD, and pVO2.
Comparison of paired data was performed using mean
difference, standard deviation, and Wilcoxon signed
rank test p value for each variable. A nominal p value
of <0.05 was considered statistically signiﬁcant. No
adjustment was made for multiple comparisons.
RESULTS
Between April 15, 2009 and June 20, 2011, 32 pa-
tients were screened for study inclusion; 20 wereDevice-Related Primary Safety Endpoints (6 and 12 Months)
device-related AE 50.0% (10/20) [27.2–72.8]
ated death* 5.0% (1/20) [0.1–24.9]
0 days 0.0% (0/20) [0.0–16.8]
to 12 months 5.0% (1/20) [0.1–24.9]
cal events 0.0% (0/20) [0.0–16.8]
uption* 5.0% (1/20) [0.1–24.9]
l infarction 0.0% (0/20) [0.0–16.8]
ction
d non–device infection
ipherally inserted central catheter line)
5.0% (1/20) [0.1–24.9]
infection 40.0% (8/20) [19.1–63.9]
percutaneous interface lead 5.0% (1/20) [0.1–24.9]
0.0% (0/20) [0.0–16.8]
device-related AE
al dysfunction†
5.0% (1/20) [0.1–24.9]
% (n/N) [95% conﬁdence interval]. All event types and relationship to device have
icated by the Clinical Events Committee. *Device-related adverse event of aortic
t time of re-do surgery for mediastinitis with an outcome of death. †Computed to-
ith contrast for the assessment of possible device infection resulted in acute renal
.
erse event.conﬁrmed eligible and implanted and 12 were con-
sidered as screen failures. Reasons for exclusion
included ascending aortic disease or nonconforming
dimensions (n ¼ 3), decreased functional capacity
(6MWD and/or pV02 below criteria, n ¼ 2), with-
drawal of consent or were withdrawn by the
investigator (n ¼ 5), left ventricular ejection frac-
tion >35% (n ¼ 1), and recent stroke (n ¼ 1). The
characteristics of study participants are pre-
sented in Table 1. As required by protocol, all pa-
tients were on stable optimal medical therapy. All
had an implantable cardioverter-deﬁbrillator, and
45% had a combined biventricular pacer–implantable
cardioverter-deﬁbrillator. Characteristics of the im-
plant procedures are detailed in Table 2.
SAFETY. In general, the implant procedure was safe.
There were no operative deaths (i.e., there was no
mortality within 30 days of the implant procedure).
Three deaths occurred between 31 days and 6 months
follow-up, including 1 adjudicated as device-related.
This last patient developed a procedure-related ster-
nal wound infection post-operatively with presence of
Methicillin resistant Staphyllococcus aureus (MRSA)
in cultures. The infection remained unresolved over
several months despite repeated antibiotic treatments
and debridement. After a CT identiﬁed a ﬁstula track
from the sternum to the device, the patient was taken
to the operating room for sternectomy and pectoral
ﬂap reconstruction. During resternotomy, atrial and
aortic tears occurred, and the patient died intra-
operatively. One patient died 60 days after implant
and another at 61 days after implant; both deaths were
adjudicated as non–device related by the independent
Clinical Events Committee. One patient underwent
LVAD implant, another underwent heart transplant.
One patient had the PIL and cuff removed at the 6-
month visit because of a disrupted internal gas-line
following a fall that damaged the line. Between 6 and
12 months, 1 patient had a heart transplant, 1 received
an LVAD, 1 was weaned from therapy at 11 months for
left ventricular recovery, and 1 discontinued therapy
voluntarily and had the PIL explanted following the 6
months post-implant follow-up visit.
Some patients included in the study were in late-
stage heart failure disease. While it was our intent
to treat patients who were not candidates for LVAD or
transplant, some of these patients were evaluated for
transplant at baseline. Two patients continued having
supraventricular arrhythmia despite cardioversion
and/or ablation and went to transplant. One patient
had opted out of LVAD, but repeat arrhythmias led to
a LVAD implant. One patient was scheduled to have a
PIL replacement when the surgeon made the decision
to implant a LVAD instead.
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531One-year survival was 85%. Table 3 presents the
primary safety endpoint analysis at 6 and 12 months.
The composite device-related adverse event rate
through 6 months, as classiﬁed by the Clinical Events
Committee, was 50%. This result was inﬂuenced by
the exit site infection rate of 40%. Between 6 months
and 12 months, there were no additional patients with
device-related serious adverse events.
EFFICACY. Table 4 presents the efﬁcacy analysis at 6
and 12 months. Signiﬁcant improvements were noted
in NYHA functional class at both 6 and 12 months.
Four (20%) and 3 (15%) patients were asymptomatic
at 6 and 12 months, respectively, improving from
NYHA functional class IV or III to functional class I
(Figure 2). The Minnesota Living with Heart Failure
QoL score signiﬁcantly improved at 6 and 12 months.
The Kansas City Cardiomyopathy Questionnaire score
also signiﬁcantly improved at 6 and 12 months. The
6MWD showed a trend toward improvement at 6
months and signiﬁcantly improved at 12 months.
There was no improvement in pVO2 at 6 months.
There was a low rate of heart failure hospitalization
in these patients. Over 12 months, 3 of the 20
implanted patients (15%) had 5 Clinical Events Com-
mittee–adjudicated heart failure hospitalizations.
Few of these occurred during active therapy, and
C-Pulse System nonadherence appeared to be related
to most of these heart failure hospitalizations; spe-
ciﬁcally, 2 of these 3 patients were nonadherent
(utilizing the system <30% of the time) in the weeks
before their heart failure hospitalizations. Over 12
months, there were 40 non–heart failure related
hospitalizations in 19 patients. Of these, 10 were
related to PIL issues in 9 patients (45%), 11 to exit
site infections in 8 patients (40%), 7 to other in-
fections (urinary tract infection, sternal wound,TABLE 4 Efﬁcacy Analyses at 6 and 12 Months
NYHA MLWHF
Baseline
(n ¼ 20)
3.1  0.3 64.4  17.6
Baseline
(n ¼ 15*)
3.1  0.3 63.6  19.9
6 months
(n ¼ 15*)
1.9  0.7 40.2  23.2
Mean change –1.1  0.7 (<0.0005) –23.4  19.0 (0.0005) 24
Baseline
(n ¼ 12)
3.1  0.3 61.0  19.2
12 months
(n ¼ 12)
1.9  0.7 36.4  21.7
Mean change –1.2  0.8 (0.0002) –24.6  16.5 (0.0005) 46
Values are mean  SD for baseline, 6-month, and 12-month numbers. Mean change are m
peak oxygen consumption (pVO2). For Minnesota Living with Heart Failure (MLWHF), l
improvement.
6MWD ¼ 6-min walk distance; NA ¼ not applicable; NYHA ¼ New York Heart Associapneumomediastinum, peripherally inserted central
catheter) in 4 patients (20%), and 12 to other condi-
tions (e.g., atrial ﬁbrillation, respiratory failure,
disseminated intravascular coagulation) in 9 patients.
DISCUSSION
The results of this feasibility study suggest that the
C-Pulse System may be safe and effective in patients
with moderate to severe heart failure. A majority of
patients showed improvements in NYHA functional
class and QoL scores, and statistically signiﬁcant
improvements in mean change from baseline to 6 and/
or 12 months were demonstrated for NYHA functional
class, QoL scores, and the 6MWD. Considering that
this feasibility study was neither designed nor pow-
ered to demonstrate statistically signiﬁcant improve-
ments in any of the efﬁcacy measurements, these
ﬁndings should merely be considered as preliminary
indicators of the potential efﬁcacy of the C-Pulse
System. However, in this context, the magnitude of
these improvements is clinically meaningful when
compared to prior drug and device trials in heart
failure (3,4), and occurred on top of ongoing treat-
ment with optimal heart failure drug and electro-
physiological device therapies. Further support for
these preliminary efﬁcacy signals includes the suc-
cessful weaning of inotropes in all patients receiving
inotropes at baseline and the reduction in diuretic
requirements in 6 patients (30%), implying improved
cardiac output and peripheral perfusion. There was no
increase in diuretics for any of the patients in the
study. These ﬁndings require conﬁrmation in an
adequately powered randomized controlled trial.
From the safety standpoint, the composite adverse
event assessment was dominated by the incidence of6MWD KCCQ-Overall KCCQ-Clinical pVO2
275.5  64.0 41.0  18.7 47.9  21.3 14.3  3.4
272.3  63.4 43.6  21.1 51.3  23.6 14.5  3.6
296.4  104.9 65.6  19.0 69.0  21.5 13.1  4.4
.1  62.6 (0.2239) 22.0  15.6 (0.0002) 17.7  12.7 (<0.0001) –1.4  3.7 (0.2612)
289.7  48.9 47.7  21.0 56.3  23.2 NA
336.5  91.8 67.4  21.1 73.6  20.7 NA
.8  64.9 (0.0425) 19.7  17.3 (0.0024) 17.3  16.2 (0.0093) NA
ean difference of the differences between the matched pairs  SD (Wilcoxon signed rank test p value). *N ¼ 14 for
ower score indicates improvement; for Kansas City Cardiomyopathy Questionnaire (KCCQ), higher scores indicate
tion.
FIGURE 2 Efﬁcacy Outcomes From Baseline to 6 and 12 Months
(A) Change in New York Heart Association (NYHA) functional class from baseline to 6 and 12 months. (B) Change in Minnesota Living with Heart
Failure (MLWHF) score from baseline to 6 and 12 months (score decrease indicates improvement). (C) 6-min walk distance from baseline to 6
and 12 months. (D) Change in Kansas City Cardiomyopathy Questionnaire Overall score (KCCQ-OS) from baseline to 6 and 12 months (score
increase represents improvement). (E) Change in Kansas City Cardiomyopathy Questionnaire Clinical score (KCCQ-CS) from baseline to 6 and 12
months (score increase represents improvement). (F) Change in peak oxygen consumption (peak VO2) from baseline to 6 months (no car-
diopulmonary exercise [CPX] test performed at 12 months, per protocol). All p values were computed using Wilcoxon signed rank test; p6Mo for
paired data comparison between baseline and 6 months, p12Mo for paired data comparison between baseline and 12 months. All p values were
calculated for educational purposes. No adjustments were made for multiple comparisons.
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532manageable exit site infections, which might be
mitigated in the future by recently developed stra-
tegies for better drive line ﬁxation and management.
There were no neurological events, myocardial
infarctions or periprocedural mortality. For the 12-
month period, there was 1 device-related death re-
ported, attributed to complications arising from a
sternal wound infection in a patient who underwent
repeated sternotomies and attempted sternectomy.
With stricter guidelines for exit site management,
including wound care, improved PIL ﬁxation, regi-
mented antibiotic therapy, as well as a less invasive(i.e., mini-thoracotomy vs. full sternotomy) approach
to C-Pulse System implantation, the exit site infec-
tion risk may be reduced in future studies.
C-Pulse patients did not experience rehospitali-
zations for stroke, thrombosis, sepsis, and bleeding
as is often observed with LVADs. This observation
is consistent with the non–blood contacting design of
C-Pulse as compared with LVADs. Another important
difference between C-Pulse and LVADs is the non-
obligatory nature of the system. The non–blood
contacting nature of the C-Pulse System allows the
device to be intermittently turned off as tolerated
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533for patient convenience. While this may improve
patient acceptance of the system, it does create the
possibility of poor patient adherence to the therapy. As
observed in the present study, nonadherence to ther-
apy might diminish the potential beneﬁts of the sys-
tem; future studies of this device must take this into
account. Strategies to assure high levels of patient
adherence to the therapy have been developed.
STUDY LIMITATIONS. This study is limited by its
small size and the absence of a parallel control group.
However, it was intended only to provide further
proof-of-concept and enough preliminary data to
support the design and conduct of a more deﬁnitive
randomized controlled trial of the C-Pulse System.
While measures of functional status and QoL were
improved, pVO2 was not. This may indicate that the
effect of C-Pulse therapy is primarily on improving
submaximal exercise, or this ﬁnding may simply
represent the inherent limitations of metabolic exer-
cise testing (19). The improvement in 6MWD supports
a potential improvement in submaximal exercise ca-
pacity with C-Pulse.The present feasibility study suggests that the C-
Pulse System may be safe in patients with moderate
to severe heart failure. It also offers preliminary
insight into the potential effectiveness of the therapy
in these patients. On the basis of review of the
feasibility study data, a prospective, randomized,
controlled trial designed to demonstrate and extend
these observations was approved by the U.S. Food
and Drug Administration in November 2012 and is
currently underway.
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